Pfizer Inc. (NYSE:PFE) was downgraded by analysts at Jefferies Group to a “hold” rating in a report released on Thursday.

Several other equities analysts have also recently issued reports on PFE. Deutsche Bank AG restated a “buy” rating on shares of Pfizer in a research note on Wednesday, June 15th. Piper Jaffray Cos. restated an “overweight” rating and set a $54.00 price objective on shares of Pfizer in a research note on Monday, June 27th. Vetr upgraded Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price objective on the stock in a research note on Monday, June 27th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, July 20th. Finally, BMO Capital Markets restated a “buy” rating and set a $40.00 price objective on shares of Pfizer in a research note on Thursday, July 21st. Eleven analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Pfizer has an average rating of “Buy” and a consensus price target of $38.78.

Analyst Recommendations for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) opened at 33.07 on Thursday. The firm has a market capitalization of $200.59 billion, a PE ratio of 29.32 and a beta of 0.86. Pfizer has a 1-year low of $28.25 and a 1-year high of $37.39. The stock’s 50 day moving average is $34.14 and its 200-day moving average is $34.26.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The company earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.56 EPS. Equities research analysts forecast that Pfizer will post $2.46 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.63%. Pfizer’s payout ratio is presently 95.24%.

A number of large investors have recently made changes to their positions in PFE. Ronna Sue Cohen raised its stake in shares of Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 35 shares during the last quarter. Forte Capital LLC ADV raised its stake in shares of Pfizer by 0.4% in the first quarter. Forte Capital LLC ADV now owns 8,589 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 36 shares in the last quarter. Delphi Private Advisors LLC raised its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 47 shares in the last quarter. Acadia Trust NA raised its stake in shares of Pfizer by 0.5% in the second quarter. Acadia Trust NA now owns 14,032 shares of the biopharmaceutical company’s stock valued at $494,000 after buying an additional 67 shares in the last quarter. Finally, New England Private Wealth Advisors LLC raised its stake in shares of Pfizer by 0.4% in the second quarter. New England Private Wealth Advisors LLC now owns 18,135 shares of the biopharmaceutical company’s stock valued at $639,000 after buying an additional 77 shares in the last quarter. Hedge funds and other institutional investors own 69.66% of the company’s stock.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.